Economics
This page lists 295 references in the Main Healthy Skepticism Library relevant to Economics.
Click on the HSL (Health Skepticism Library) number for more details which may include an abstract or full text.
HSL6877
Tartaglia LA.
Complementary new approaches enable repositioning of failed drug candidates.
Expert Opin Investig Drugs 2006 Nov 01;15(11):1295-8
http://www.expertopin.com/doi/abs/10.1517/13543784.15.11.1295
HSL6975
Tonby K.
[Forgotten diseases and new drugs].
Tidsskr Nor Laegeforen 2006 Oct 19;126(20):2694-6
http://www.tidsskriftet.no/pls/lts/pa_lt.visSeksjon?vp_SEKS_ID=1443907
HSL6786
Shuchman M.
Delaying generic competition--corporate payoffs and the future of Plavix.
N Engl J Med 2006 Sep 28;355(13):1297-300
http://content.nejm.org/cgi/content/extract/355/13/1297
HSL6883
Johnston BC, Vohra S.
Investigator-initiated trials are more impartial.
Nature 2006 Sep 14;443(7108):144
http://www.nature.com/doifinder/10.1038/443144a
HSL6739
Pollack A.
The wide, wild world of genetic testing.
NY Times (Print) 2006 Sep 12;NYT4
HSL6788
Lassen LC, Thomsen MK.
[Global health--the ethical responsibility of the pharmaceutical industry].
Ugeskr Laeger 2006 Sep 4;168(36):2994-5
HSL6665
Shrank WH, Joseph GJ, Choudhry NK, Young HN, Ettner SL, Glassman P, Asch SM, Kravitz RL.
Physicians' perceptions of relevant prescription drug costs: do costs to the individual patient or to the population matter most?
Am J Manag Care 2006 Sep 01;12(9):545-51
http://www.ajmc.com/Article.cfm?ID=3191&CFID=3768231&CFTOKEN=45537093
HSL6668
Dormont B, Grignon M, Huber H.
Health expenditure growth: reassessing the threat of ageing.
Health Econ 2006 Sep 01;15(9):947-63
http://www3.interscience.wiley.com/cgi-bin/abstract/112776605/ABSTRACT?CRETRY=1&SRETRY=0
HSL6686
Sleeping pills: are they worth the risk?
Consum Rep 2006 Sep 01;71(9):48-9
HSL6798
Tandon R.
Comparing antipsychotic efficacy.
Am J Psychiatry 2006 Sep 01;163(9):1645
http://ajp.psychiatryonline.org/cgi/content/full/163/9/1645
HSL6886
Fehr A, Thurmann P, Razum O.
Editorial: drug development for neglected diseases: a public health challenge.
Trop Med Int Health 2006 Sep 01;11(9):1335-8
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-3156.2006.01714.x
HSL6774
More fizz at Pfizer?
Nature 2006 Aug 17;442(7104):734
http://www.nature.com/doifinder/10.1038/442734a
HSL6535
Mintzberg H.
Patent nonsense: evidence tells of an industry out of social control.
CMAJ 2006 Aug 15;175(4):374
http://www.cmaj.ca/cgi/content/full/175/4/374
HSL6536
Kondro W.
Brand-name drug companies fail to meet R&D commitments.
CMAJ 2006 Aug 15;175(4):344
http://www.cmaj.ca/cgi/content/full/175/4/344
HSL6537
Silversides A.
Pharmacies receiving massive rebates from generic drug-makers.
CMAJ 2006 Aug 15;175(4):342
http://www.cmaj.ca/cgi/content/full/175/4/342
HSL6742
Taylor M.
Are hospitals next in line? Government investigators probing relationships between physicians, devicemakers may soon train sights on hospitals.
Mod Healthc 2006 Aug 14;36(32):24-6
HSL6747
Vermeulen M.
[Sponsoring of research by the industry is not good for science].
Ned Tijdschr Geneeskd 2006 Aug 12;150(32):1769
HSL6748
Raaijmakers JA.
[Research sponsored by the industry benefits scientific progress].
Ned Tijdschr Geneeskd 2006 Aug 12;150(32):1768
HSL6693
Nestle M.
Food industry and health: mostly promises, little action.
Lancet 2006 Aug 12;368(9535):564-5
http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(06)69177-0
HSL6771
Sloane T.
Bad medicine. Big Pharma's cash injections lead to poor ethical outcomes.
Mod Healthc 2006 Aug 7;36(31):19
HSL6541
The business of HIV/AIDS.
Lancet 2006 Aug 5;368(9534):423
http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(06)69124-1
HSL6419
Roumeliotis G.
Is big pharma killing innovation in drug formulation? - GSK defends the industry
In-Pharmatechnologist 2006 Aug 3
http://www.in-pharmatechnologist.com/news/ng.asp?n=69490-bionet-glaxosmithkline-formulations-delivery-systems-exubera
HSL6549
Cromer BA, Scholes D, Berenson A, Cundy T, Clark MK, Kaunitz AM; Society for Adolescent Medicine.
Depot medroxyprogesterone acetate and bone mineral density in adolescents--the Black Box Warning: a Position Paper of the Society for Adolescent Medicine.
J Adolesc Health 2006 Aug 01;39(2):296-301
http://linkinghub.elsevier.com/retrieve/pii/S1054-139X(06)00098-X
HSL6697
Brogan D, Mossialos E.
Applying the concepts of financial options to stimulate vaccine development.
Nat Rev Drug Discov 2006 Aug 01;5(8):641-7
http://www.nature.com/nrd/journal/v5/n8/abs/nrd2035.html;jsessionid=76ADD4A1D11E33767FCC04F5CDFF6F5A
HSL6706
Baxter P.
Medicine and the pharmaceutical industry.
Dev Med Child Neurol 2006 Aug 01;48(8):627
http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=453299
HSL6708
Power E.
Impact of antibiotic restrictions: the pharmaceutical perspective.
Clin Microbiol Infect 2006 Aug 01;12
HSL6759
Singh R.
Clinical research in China and India: a paradigm shift in drug development.
Drug Discov Today 2006 Aug 01;11(15-16):675-6
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T64-4KDJSRH-1&_coverDate=08%2F31%2F2006&_alid=461531159&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5020&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=88c01c8110497ffd3807a6a69916127d
HSL6888
Batchelder K, Miller P.
A change in the market--investing in diagnostics.
Nat Biotechnol 2006 Aug 01;24(8):922-6
http://www.nature.com/nbt/journal/v24/n8/abs/nbt0806-922.html
HSL6889
Sheridan C.
Tysabri back on market.
Nat Biotechnol 2006 Aug 01;24(8):874
http://www.nature.com/doifinder/10.1038/nbt0806-874
HSL6890
Ransom J.
A reprise for collaborative financing in biotech.
Nat Biotechnol 2006 Aug 01;24(8):873-4
http://www.nature.com/doifinder/10.1038/nbt0806-873
HSL6205
Melnikow J, Kuenneth C, Helms LJ, Barnato A, Kuppermann M, Birch S, Nuovo J.
Chemoprevention: Drug pricing and mortality: the case of tamoxifen.
Cancer 2006 Jul 24
http://www3.interscience.wiley.com/cgi-bin/abstract/112729136/ABSTRACT?CRETRY=1&SRETRY=0
HSL6532
Carreyrou J.
Seizures of Canadian drugs rise as Congress, Customs spar.
Wall St J (East Ed) 2006 Jul 24:B1
HSL6120
Sheldon T.
Dutch consider excluding costly treatments from health insurance
BMJ 2006 Jul 15;333(7559):113
http://bmj.bmjjournals.com/cgi/content/short/333/7559/113-a?etoc
HSL5991
Roehr B.
Roche’s tiered pricing enables poorer countries to stockpile drugs
BMJ 2006 Jul 8;333(7558):63
http://bmj.bmjjournals.com/cgi/content/short/333/7558/63?etoc
HSL6844
Garber K.
Patently absurd?
Nat Biotechnol 2006 Jul 01;24(7):737-9
http://www.nature.com/doifinder/10.1038/nbt0706-737
HSL6845
Ransom J.
Pipeline cherrypicking deal yields lucrative return.
Nat Biotechnol 2006 Jul 01;24(7):729
http://www.nature.com/doifinder/10.1038/nbt0706-729
HSL5948
Zarocostas J.
Drug company chief urges faster introduction of new vaccines in poor nations.
BMJ 2006 Jul 1;333(7557):11
http://bmj.bmjjournals.com/cgi/content/short/333/7557/11-a?etoc
HSL6150
Funding of patients' groups.
Lancet 2006 Jul 1;368(9529):2
http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(06)68941-1
HSL6151
Rigby N.
Obesity association clarifies definitions of obesity and links with drug firms.
BMJ 2006 Jul 1;333(7557):44
http://bmj.bmjjournals.com/cgi/content/full/333/7557/44
HSL6542
Halkin H.
The evidence behind our evidence-based decisions: cheques and balances.
Isr Med Assoc J 2006 Jul 01;8(7):494-6
HSL6555
Gillman K.
Disease mongering: one of the hidden consequences.
PLoS Med 2006 Jul 01;3(7):e316
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=16848621
HSL6760
Refolo LM, Fillit HM.
Partnerships between philanthropy, government and industry are needed to advance drug discovery for neurodegenerative diseases.
Curr Alzheimer Res 2006 Jul 01;3(3):175-6
http://www.ingentaconnect.com/content/ben/car/2006/00000003/00000003/art00001?token=004d1972c233caaeb582a2f4876753375686f4957275c277b422c31465d486b25622c507959fa
HSL6778
Kesselman I, Elstein D, Israeli A, Chertkoff R, Zimran A.
National health budgets for expensive orphan drugs: Gaucher disease in Israel as a model.
Blood Cells Mol Dis 2006 Jul-Aug 01;37(1):46-9
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WBV-4KBVX2J-1&_coverDate=08%2F31%2F2006&_alid=461573438&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=6720&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=83f7ee4aa8007986e8dfb3dfcda5e1c6
HSL6804
Spatz ID.
Vouchers for FDA priority reviews.
Health Aff (Millwood) 2006 Jul-Aug 01;25(4):1184
http://content.healthaffairs.org/cgi/content/full/25/4/1184
HSL6494
Polak M.
Viewpoint: megatrials and the development of antithrombotics.
Circulation 2006 Jun 27;113(25):f97
http://circ.ahajournals.org/cgi/reprint/113/25/f97
HSL6219
Hoeg E.
[Small patients--big challenges].
Tidsskr Nor Laegeforen 2006 Jun 22;126(13):1764
http://www.tidsskriftet.no/pls/lts/pa_lt.visSeksjon?vp_SEKS_ID=1396927
HSL6215
Lafolie P.
[Final reply: drug companies must be allowed to make profit].
Lakartidningen 2006 Jun 14-27;103(24-25):1979
HSL6551
Weiss R.
'Serious misconduct' by NIH expert found: scientist did not report sending tissues to drug firm and getting paid, report says.
Washington Post 2006 Jun 14:A6
HSL6100
Mantone J.
Making research pay. Reaping rewards, conflicts for developing drugs.
Mod Healthc 2006 Jun 12;36(24):17-8
HSL5730
Watson R.
EU offers incentives to firms to produce medicines for children.
BMJ 2006 Jun 10;332(7554):1352
http://bmj.bmjjournals.com/cgi/content/full/332/7554/1352-c
HSL5733
Richards T.
The great medicines scandal.
BMJ 2006 Jun 10;332(7554):1345-6
http://bmj.bmjjournals.com/cgi/content/full/332/7554/1345
HSL5578
Klok RM, Boersma C, Oosterhuis I, Visser ST, DE Jong-VAN DEN Berg LT, Postma MJ.
Switch patterns before and after patent expiry of omeprazole: a case study in The Netherlands.
Aliment Pharmacol Ther 2006 Jun 1;23(11):1595-600
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2036.2006.02921.x
HSL5931
Mabasa VH, Ma J.
Effect of a Therapeutic Maximum Allowable Cost (MAC) Program on the Cost and Utilization of Proton Pump Inhibitors in an Employer-Sponsored Drug Plan in Canada.
J Manag Care Pharm 2006 Jun 01;12(5):371-6
HSL5977
Johnson DH.
Keynote comment: Cancer drug pricing in the USA.
Lancet Oncol 2006 Jun 01;7(6):444-5
http://linkinghub.elsevier.com/retrieve/pii/S1470-2045(06)70702-1
HSL6148
Lanier WL.
Editor's note: Industry support of articles published in Mayo Clinic Proceedings.
Mayo Clin Proc 2006 Jun 01;81(6):851-2
HSL6222
Ruel MD.
Using race in clinical research to develop tailored medications. Is the FDA encouraging discrimination or eliminating traditional disparities in health care for African Americans?
J Leg Med 2006 Jun 01;27(2):225-41
http://taylorandfrancis.metapress.com/(nhajxw55xm42kfmxadioudb5)/app/home/contribution.asp?referrer=parent&backto=issue,4,6;journal,1,26;linkingpublicationresults,1:102467,1
HSL6325
Montgomery JH.
Industry funding and author-industry affiliation in clinical trials in psychiatry.
Am J Psychiatry 2006 Jun 01;163(6):1110-1
http://ajp.psychiatryonline.org/cgi/content/full/163/6/1110
HSL5735
Ferner RE, McDowell SE.
How NICE may be outflanked.
BMJ 2006 May 27;332(7552):1268-71
http://bmj.bmjjournals.com/cgi/content/full/332/7552/1268
HSL5616
Silversides A.
Monitoring the price of new drugs.
CMAJ 2006 May 23;174(11):1548-9
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3051&uid=16717260&db=PubMed&url=http://www.cmaj.ca/cgi/pmidlookup?view=long&pmid=16717260
HSL5741
Firestone RA.
Drug giants hamstrung by timid middle management.
Nature 2006 May 18;441(7091):282
http://www.nature.com/doifinder/10.1038/441282b
HSL5489
Spence D.
Research for profit.
BMJ 2006 May 13;332(7550):1155-1156
http://bmj.bmjjournals.com/cgi/content/full/332/7550/1155-c
HSL5622
Watson R.
EU companies can export generic versions of patented drugs to poor countries.
BMJ 2006 May 13;332(7550):1112
http://bmj.bmjjournals.com/cgi/content/full/332/7550/1112-a
HSL5664
Check E.
Are rich nations up for drug reform?
Nature 2006 May 11;441(7090):135
http://www.nature.com/doifinder/10.1038/441135a
HSL5613
Saul S.
Doctors object as drug makers learn who's prescribing what.
NY Times (Print) 2006 May 4;A1
HSL6220
Brock DW.
How much is more life worth?
Hastings Cent Rep 2006 May-Jun 01;36(3):17-9
HSL6328
Williams R, Marion J.
Are drug too expensive in Canada? No
Can Fam Physician 2006 May 01;52:573-6, 578-81
HSL6329
Lexchin J.
Are drugs too expensive in Canada? Yes
Can Fam Physician. 2006 May 01;52:573-6, 578-81
http://www.cfpc.ca/cfp/2006/May/vol52-may-debates-1.asp
HSL6563
Edwards M, Murray F, Yu R.
Gold in the ivory tower: equity rewards of outlicensing.
Nat Biotechnol 2006 May 01;24(5):509-15
HSL6566
Ransom J.
Are small biotechs still underselling themselves?
Nat Biotechnol 2006 May 01;24(5):477
http://www.nature.com/doifinder/10.1038/nbt0506-477
HSL5595
The future should not look like the past.
Lancet Infect Dis 2006 May;6(5):253
http://linkinghub.elsevier.com/retrieve/pii/S1473-3099(06)70441-8
HSL5566
Carey B.
Study cites links to firms by psychiatrists.
NY Times (Print) 2006 Apr 20;:A23
HSL5497
Dyer O.
Nine drug company chiefs are charged with conspiracy to defraud NHS.
BMJ 2006 Apr 15;332(7546):872
http://bmj.bmjjournals.com/cgi/content/full/332/7546/872-c
HSL5499
Lexchin J.
Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices
CMAJ 2006 Apr 11;174(8):1120-1
http://www.cmaj.ca/cgi/content/full/174/8/1120
HSL5565
Benko LB.
Drug lawsuits building. Merck, Pfizer facing charges of misrepresentation.
Mod Healthc 2006 Apr 10;36(15):16
HSL5648
Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga CA, Freedman R.
Conflict of interest.
Am J Psychiatry 2006 Apr;163(4):571-3
http://ajp.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=16585427
HSL5649
Hill KP.
Free lunch?
Am J Psychiatry 2006 Apr;163(4):569-70
http://ajp.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=16585426
HSL5376
Make or break time in Vioxx drama.
Nature 2006 Mar 16;440(7082):277
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3094&uid=16541045&db=PubMed&url=http://dx.doi.org/10.1038/440277a
HSL5397
Werko L.
[The 'innovative' drug industry]
Lakartidningen 2006 Mar 15-21;103(11):857
HSL6809
Unger T.
[Innovation or pseudo-innovation: that is the question].
Med Klin (Munich) 2006 Mar 15;101(3):257-62
HSL5584
Pollack A.
Take your pills, all your pills: drug makers nag patients to stay the course.
NY Times (Print) 2006 Mar 11;C1
HSL6849
Ridley DB, Kramer JM, Tilson HH, Grabowski HG, Schulman KA.
Spending on postapproval drug safety.
Health Aff (Millwood) 2006 Mar-Apr 01;25(2):429-36
http://content.healthaffairs.org/cgi/content/full/25/2/429
HSL5032
Hilliard T, Chambers T.
The relationship between paediatricians and commerce.
Paediatr Respir Rev 2006 Mar;7(1):54-9
http://linkinghub.elsevier.com/retrieve/pii/S1526-0542(05)00086-2
HSL5359
Jeppsson A.
[Drug development costs are overstated by the industry].
Lakartidningen 2006 Mar 1-7;103(9):663-4
HSL5361
Anderson JC, Narus JA, van Rossum W.
Customer value propositions in business markets.
Harv Bus Rev 2006 Mar 01;84(3):90-9,
HSL5660
Engelman K.
Rx: professional integrity (prn).
J Clin Hypertens (Greenwich) 2006 Mar 01;8(3):232
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3351&uid=16578956&db=PubMed&url=http://www.lejacq.com/articleDetail.cfm?pid=JClinHypertens_8;3:232
HSL5687
Levin PJ, McGee G.
Physician, divest thyself.
Am J Bioeth 2006 Mar-Apr 01;6(2):1-2
http://taylorandfrancis.metapress.com/(xejiig55vu0ome45n4xojl45)/app/home/contribution.asp?referrer=parent&backto=issue,1,44;journal,2,25;linkingpublicationresults,1:111605,1
HSL5751
Mack J.
Counterpoint: biotech needs more than DTC as usual.
Nat Biotechnol 2006 Mar 01;24(3):267
http://www.nature.com/nbt/journal/v24/n3/full/nbt0306-267.html
HSL5987
Ferrara J.
Personalized medicine: challenges in assessing and capturing value in the commercial environment.
Expert Rev Mol Diagn 2006 Mar 01;6(2):129-31
http://www.future-drugs.com/doi/abs/10.1586/14737159.6.2.129
HSL6221
Dandona L.
Clinical trials in India: balancing economic opportunity with the public health context.
Natl Med J India 2006 Mar-Apr 01;19(2):57-9
HSL6850
Adams CP, Brantner VV.
Estimating the cost of new drug development: is it really 802 million dollars?
Health Aff (Millwood) 2006 Mar-Apr 01;25(2):420-8
http://content.healthaffairs.org/cgi/content/full/25/2/420
HSL6851
Ridley DB, Grabowski HG, Moe JL.
Developing drugs for developing countries.
Health Aff (Millwood) 2006 Mar-Apr 01;25(2):313-24
http://content.healthaffairs.org/cgi/content/full/25/2/313
HSL6852
Drugs and vaccines around the world.
Health Aff (Millwood) 2006 Mar-Apr 01;25(2):312
http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?itool=Citation-def&PrId=3051&uid=16522572&db=PubMed&url=http://content.healthaffairs.org/cgi/pmidlookup?view=long&pmid=16522572
HSL5335
Burton TM.
Amid alarm bells, a blood substitute keeps pumping; ten in trial have heart attacks, but data aren't published; FDA allows a new study; doctors' pleas are ignored.
Wall St J (East Ed) 2006 Feb 22;A1
HSL5500
Guglielmo WJ.
Scheduling drug reps online.
Med Econ 2006 Feb 17;83(4):49-50,
HSL5506
Berenson A.
A cancer drug shows promise, at a price that many can't pay.
NY Times (Print) 2006 Feb 15;A1
HSL5323
McKillop T.
Does the European pharmaceutical industry have a future?
Circulation 2006 Feb 7;113(5):f19-20
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3051&uid=16468149&db=PubMed&url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=16468149
HSL5306
Nystrand A.
[The examples Cancer Foundation, Heart-Lung foundation and Child Cancer Foundation: aggressive marketing undermines confidence].
Lakartidningen 2006 Feb 1-7;103(5):306-7
HSL5568
Ricevuti G, Gasparetto C.
Re: Bioethics, the Surviving Sepsis Campaign, and the industry.
Wien Klin Wochenschr 2006 Feb;118(1-2):64-5
HSL5569
Mackenzie AF.
Re: Bioethics, the Surviving Sepsis Campaign, and the industry.
Wien Klin Wochenschr 2006 Feb;118(1-2):64
HSL5570
Malliani A.
Re: Bioethics, the Surviving Sepsis Campaign, and the industry.
Wien Klin Wochenschr 2006 Feb;118(1-2):63-4
HSL5572
Bion J, Vincent JL, Angood P.
Bioethics, the Surviving Sepsis Campaign and the industry.
Wien Klin Wochenschr 2006 Feb;118(1-2):63
HSL5623
Ridgway WE.
Realizing two-tiered innovation policy through drug regulation.
Stanford Law Rev 2006 Feb;58(4):1221-50
HSL5272
Jarhult B.
[Let the profit from drug advertisement in Lakartidningen go to a research foundation!].
Lakartidningen 2006 Jan 25-31;103(4):226
HSL5339
Harris G.
In article, doctors back ban on drug companies' gifts; concerns cited on quality of patient care.
NY Times (Print) 2006 Jan 25;A14
HSL5235
Fontanarosa PB, DeAngelis CD.
JAMA's policy on industry sponsored studies.
BMJ 2006 Jan 21;332(7534):177
http://bmj.bmjjournals.com/cgi/content/full/332/7534/177
HSL5261
Herrling P.
Experiments in social responsibility.
Nature 2006 Jan 19;439(7074):267-8
http://www.nature.com/doifinder/10.1038/439267a
HSL5674
Lazarus A.
The role of the pharmaceutical industry in medical education in psychiatry.
Acad Psychiatry 2006 Jan-Feb 01;30(1):40-4
http://ap.psychiatryonline.org/cgi/content/full/30/1/40
HSL5675
Jibson MD.
Medical education and the pharmaceutical industry: managing an uneasy alliance.
Acad Psychiatry 2006 Jan-Feb 01;30(1):36-9
http://ap.psychiatryonline.org/cgi/content/full/30/1/36
HSL6764
Vogenberg FR, Dhir S.
Have consultant pharmacists provided value to long-term care payers?
Consult Pharm 2006 Jan 01;21(1):72-5
HSL5311
Jayaraman KS.
Firms discovering reality of clinical research in India.
Nat Rev Drug Discov 2006 Jan;5(1):6
HSL5346
Windmeijer F, de Laat E, Douven R, Mot E.
Pharmaceutical promotion and GP prescription behaviour.
Health Econ 2006 Jan;15(1):5-18
http://www3.interscience.wiley.com/cgi-bin/abstract/110504860/ABSTRACT
HSL5386
Finucane TE.
Advertising the new hypnotics.
J Am Geriatr Soc 2006 Jan;54(1):170
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1532-5415.2005.00575_1.x
HSL6744
Vandereycken W.
[Bitter and gilded pills: psychiatry in the light (or shadow) of the pharmaceutical industry].
Tijdschr Psychiatr 2006;48(2):119-29
HSL6745
Rubsaam J.
[Reaction to 'About the comparison of public-private cooperation'].
Tijdschr Psychiatr 2006;48(4):343;
HSL5347
Wogart JP, Calcagnotto G.
Brazil's fight against AIDS and its implications for global health governance.
Healthc Q 2006;9(1):76-89
HSL5605
Lee R.
FDA and drug safety: new Tufts study challenges critics of the Prescription Drug User Fee Act.
J Law Med Ethics 2006 Spr;34(1):131-4
HSL5981
Vernon JA, Johnson SJ, Hughen WK, Trujillo A.
Economic and developmental considerations for pharmacogenomic technology.
Pharmacoeconomics 2006;24(4):335-43
HSL5982
Hughes D.
Rationing of drugs for rare diseases.
Pharmacoeconomics 2006;24(4):315-6
HSL6562
Dresser R.
Private-sector research ethics: marketing or good conflicts management The 2005 John J. Conley Lecture on Medical Ethics
Theor Med Bioeth. 2006;27(2):115-39 2006;27(2):115-39
http://www.springerlink.com/content/bq855531108k52p6/
HSL6733
Smith SW, Atkin CK, Roznowski J.
Are 'drink responsibly' alcohol campaigns strategically ambiguous?
Health Commun 2006;20(1):1-11
http://www.leaonline.com/doi/abs/10.1207/s15327027hc2001_1
HSL6810
Cosgrove L, Krimsky S, Vijayaraghavan M, Schneider L.
Financial ties between DSM-IV panel members and the pharmaceutical industry.
Psychother Psychosom 2006;75(3):154-60
http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=PPS2006075003154
HSL6835
Belgers T.
[Reaction to 'About the comparison of public-private cooperation. Comment on Vandereycken']
Tijdschr Psychiatr 2006;48(7):601-2
HSL6836
Buis WM.
[Reaction to 'Bitter and gilded pills: psychiatry in the light (or shadow) of the pharmaceutical industry' and to 'The importance of public-private cooperation. Comment on Vandereycken']
Tijdschr Psychiatr. 2006;48(6):500-1
HSL5352
Activists lift boycott of Abbott Laboratories.
AIDS Policy Law 2005 Dec 30;21(1):2
HSL5264
Steele FR.
Big Pharma's Commedia.
Cell 2005 Dec 16;123(6):971-3
http://linkinghub.elsevier.com/retrieve/pii/S0092-8674(05)01321-8
HSL5403
Anand G.
Support system: through charities, drug makers help people--and themselves.
Wall St J (East Ed) 2005 Dec 1;A1
HSL5678
Bednarik J.
Does brand differentiate pharmaceuticals?
Neuro Endocrinol Lett 2005 Dec 01;26(6):635-52
HSL5353
Lichtenberg FR.
Pharmaceutical innovation and the burden of disease in developing and developed countries.
J Med Philos 2005 Dec;30(6):663-90
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3396&uid=16396790&db=PubMed&url=http://taylorandfrancis.metapress.com/openurl.asp?genre=article&issn=0360-5310&volume=30&issue=6&spage=663
HSL5038
Henry DA, Hill SR, Harris A.
Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
JAMA 2005 Nov 23;294(20):2630-2
http://jama.ama-assn.org/cgi/content/full/294/20/2630
HSL5405
Anand G.
Why Genzyme can charge so much for Cerezyme.
Wall St J (East Ed) 2005 Nov 16;A15
HSL5406
Uncertain miracle: a biotech drug extends a life, but at what price? For Ms. Lees, treatment bill now totals $7 million; her bones keep crumbling; guilt of another $1,400 day.
Wall St J (East Ed) 2005 Nov 16;A1,
HSL5221
Klein BE, Dalby KJ.
Nonprofit drug companies.
Health Aff (Millwood) 2005 Nov-Dec;24(6):1684-5
http://content.healthaffairs.org/cgi/content/full/24/6/1684
HSL5265
Curtiss FR.
Who Needs XR, LA, SR, XL, ER, or CR?
J Manag Care Pharm 2005 Nov-Dec;11(9):772-3,
HSL5266
Hong SH, Shepherd MD, Scoones D, Wan TT.
Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
J Manag Care Pharm 2005 Nov-Dec;11(9):746-54
HSL5324
Openshaw MS.
The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.
Nurs Econ 2005 Nov-Dec;23(6):307-11,
HSL5737
Hall SS.
The short of it: more short children are being given growth hormone in the hope that an extra inch will protect their supposedly fragile psyches. But research suggests that their height is a problem less for them than for us.
N Y Times Mag 2005 Oct 16;:54-9
HSL5061
Adams CD.
Doctors and the drug industry: reader feedback.
Am J Med 2005 Oct;118(10):1177
http://linkinghub.elsevier.com/retrieve/pii/S0002-9343(05)00203-2
HSL5063
Warrier R, Houghton B.
Doctors and the drug industry: reader feedback.
Am J Med 2005 Oct;118(10):1175-6
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3048&uid=16194656&db=PubMed&url=http://linkinghub.elsevier.com/retrieve/pii/S0002-9343(05)00277-9
HSL6718
Kirk DD, Robert JS.
Assessing commercial feasibility: a practical and ethical prerequisite for human clinical testing.
Account Res 2005 Oct-Dec 01;12(4):281-97
HSL5234
Ballantyne A.
HIV international clinical research: exploitation and risk.
Bioethics 2005 Oct;19(5-6):476-91
HSL5267
Couzos S.
PBS medications--improving access for Aboriginal and Torres Strait Islander peoples.
Aust Fam Physician 2005 Oct;34(10):841-4
http://www.racgp.org.au/document.asp?id=18314
HSL6841
Nyigo VA, Malebo HM.
Drug discovery and developments in developing countries: bottlenecks and way forward.
Tanzan Health Res Bull 2005 Sep 01;7(3):154-8
HSL6572
Moran M.
A breakthrough in R&D for neglected diseases: new ways to get the drugs we need.
PLoS Med 2005 Sep 01;2(9):e302
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=16138789
HSL6575
Fischer A, Borensztein P, Roussel C.
The European rare diseases therapeutic initiative.
PLoS Med 2005 Sep 01;2(9):e243
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=16104832
HSL5249
Connolly M.
Keeping the boat afloat: tips on fundraising strategies for your chapter.
Imprint 2005 Sep-Oct;52(4):50-1
HSL5270
Huskamp HA, Shinogle JA.
Economic grand rounds: potential effects of the new medicare drug benefit on pricing for psychotropic medications.
Psychiatr Serv 2005 Sep;56(9):1056-8
http://ps.psychiatryonline.org/cgi/content/full/56/9/1056
HSL5279
Carroll J.
Plans struggle for control of specialty pharma costs.
Manag Care 2005 Sep;14(9):41-2
HSL2671
Numerof RE, Nightingale J.
Guest Opinion: R&D Prioritization - Going beyond decision analysis
eyeforpharma Briefing 2005 Aug 17(151)
http://www.eyeforpharma.com/index.asp?nli=o&g-p&nld=8/17/2005&news=47331
HSL5075
Davies A, Metcalfe S, Moodie P, McNee W.
PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonists.
N Z Med J 2005 Aug 12;118(1220):U1621
HSL2843
Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW.
Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance.
JAMA 2005 Aug 10;294(6):716-24
http://jama.ama-assn.org/cgi/content/full/294/6/716
HSL4054
Glaxo inks AIDS vaccine deal with nonprofit.
AIDS Read 2005 Aug 01;15(8):391
HSL4214
Frank RG.
Looking for truth in all the wrong places.
Med Care 2005 Aug 01;43(8):751-2
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3159&uid=16034287&db=pubmed&url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0025-7079&volume=43&issue=8&spage=751
HSL6765
Duval G.
The benefits and threats of research partnerships with industry.
Crit Care 2005 Aug 01;9(4):309-10
http://ccforum.com/content/9/4/309
HSL4197
Mervis J.
The hunt for a new drug: five views from the inside.
Science 2005 Jul 29;309(5735):722
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3051&uid=16051781&db=pubmed&url=http://www.sciencemag.org/cgi/pmidlookup?view=long&pmid=16051781
HSL5447
Walker J.
Cambridge: Europe's leading location for biotechnology.
Drug Discov Today 2005 Jul 15;10(14):956-9
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3048&uid=16023052&db=PubMed&url=http://linkinghub.elsevier.com/retrieve/pii/S1359-6446(05)03522-1
HSL5083
Hale VG, Woo K, Lipton HL.
Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world.
Health Aff (Millwood) 2005 Jul-Aug;24(4):1057-63
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3051&uid=16012146&db=PubMed&url=http://content.healthaffairs.org/cgi/pmidlookup?view=long&pmid=16012146
HSL5658
Senior K.
Neglected diseases: getting less neglected?
Drug Discov Today 2005 Jul 1;10(13):878
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3048&uid=15993802&db=PubMed&url=http://linkinghub.elsevier.com/retrieve/pii/S1359-6446(05)03519-1
HSL1918
Metherell M.
Lung cancer drugs will cost more
The Sydney Morning Herald 2005 Jun 17
http://www.smh.com.au/news/National/Lung-cancer-drugs-will-cost-more/2005/06/16/1118869048092.html
HSL1919
Pear R.
Medicare Officials Insisting on Wider Choices in Drug Benefits
The New York Times 2005 Jun 15
http://www.nytimes.com/2005/06/15/health/15drug.html?ei=5070&en=be3d33b7b081
HSL1909
Berenson A.
At Pfizer, the Isolation Increases for a Whistle-Blower: No man is an island. But Peter Rost is getting close.
2005 Jun 8
HSL5039
Rasmussen LM.
The ethics and aesthetics of for-profit bioethics consultation.
HEC Forum 2005 Jun;17(2):94-121
HSL1870
Berenson A.
Merck's New Boss Inherits a Mess
The New York Times 2005 May 21
HSL1860
Schmit J.
Costs, regulations move more drug tests outside USA
USA TODAY 2005 May 16
HSL1780
Stafford A, Allen L.
Drug companies, doctors face curbs
The Financial Review 2005 May 10
HSL1857
Dabade G.
Of patents, licences and drug prices
Deccan Herald 2005 May 10
HSL1781
Frenkel J, Harvey M, McManus G.
$800m boost for cheaper medicine
The Herald Sun 2005 May 9
HSL1865
Connolly C.
Pentagon to Drop Nexium From Its List Of Covered Drugs for Military Personnel 'Purple Pill' Nexium the First to Be Cut
The Washington Post 2005 May 8
HSL4244
Cohen AF.
[The pharmaceutical industry in uproar]
Ned Tijdschr Geneeskd 2005 May 7;149(19):1074
HSL1841
Gottlieb S.
Big Pharma's New Funk
Forbes.com 2005 May 6
HSL4248
Ahlborn H, Henderson S, Davies N.
No immediate pain relief for the pharmaceutical industry.
Curr Opin Drug Discov Devel 2005 May 01;8(3):384-91
HSL4250
Gund P, Maliski E, Brown F.
Editorial overview: whither the pharmaceutical industry?
Curr Opin Drug Discov Devel 2005 May 01;8(3):296-7
HSL5449
Kaltwasser JP, Behrens F.
Leflunomide: long-term clinical experience and new uses.
Expert Opin Pharmacother 2005 May 01;6(5):787-801
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3204&uid=15934905&db=PubMed&url=http://www.ashley-pub.com/doi/abs/10.1517/14656566.6.5.787
HSL5465
Austin S.
Drug Discovery Technology Europe 2005 - IBC's Ninth Annual Conference and Exhibition.
IDrugs 2005 May 01;8(5):370-3
HSL5466
Ulmer JB.
DNA vaccines forum: how to enhance DNA vaccines safety and potency?
IDrugs 2005 May 01;8(5):357-9
HSL1920
Offit PA.
Why are pharmaceutical companies gradually abandoning vaccines?
Health Aff (Millwood) 2005 May-Jun;24(3):622-30
http://content.healthaffairs.org/cgi/content/full/24/3/622
HSL5463
Haurum J, Bregenholt S.
Recombinant polyclonal antibodies: therapeutic antibody technologies come full circle.
IDrugs 2005 May;8(5):404-9
HSL5512
Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ.
The global threat of counterfeit drugs: why industry and governments must communicate the dangers.
PLoS Med 2005 Apr 01;2(4):e100
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0020100
HSL4261
Dong X, Fetterolf D.
Specialty pharmacy: an emerging area of interest for medical management.
Dis Manag 2005 Apr;8(2):73-85
HSL5093
Faunce TS, Tomossy GF.
The UK House of Commons report on the influence of the pharmaceutical industry: lessons for equitable access to medicines in Australia.
Monash Bioeth Rev 2005 Apr;24(2):38-42
HSL5470
Curtiss FR.
Evidence-based medicine: United States, the last venue for direct-to-consumer advertising, props up the erectile dysfunction market.
J Manag Care Pharm 2005 Mar 01;11(2):176-8
HSL5088
Mather C.
The pipeline and the porcupine: alternate metaphors of the physician-industry relationship.
Soc Sci Med 2005 Mar;60(6):1323-34
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VBF-4D5JSJJ-2&_coverDate=03%2F01%2F2005&_alid=398122182&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5925&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=a3b4c00f922432b53675cfc8e056c2cd
HSL5680
Tarzwell R.
Reader's response to the webcast video editorial entitled 'the institute for one world health--a not-for-profit pharmaceutical company'.
MedGenMed 2005 Feb 25;7(1):34
https://profreg.medscape.com/px/getlogin.do?urlCache=aHR0cDovL3d3dy5tZWRzY2FwZS5jb20vdmlld2FydGljbGUvNDk5Mzk5
HSL5679
Lundberg GD.
The Institute for One World Health--a not-for-profit pharmaceutical company.
MedGenMed 2005 Jan 7;7(1):61
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3052&uid=16369366&db=PubMed&url=http://www.medscape.com/viewarticle/496086
HSL4218
Elliott C.
Adventure! Comedy! Tragedy! Robots! How bioethicists learned to stop worrying and embrace their inner cyborgs.
J Bioeth Inq 2005;2(1):18-23
HSL5068
McCann MA.
Dietary supplement labeling: cognitive biases, market manipulation & consumer choice.
Am J Law Med 2005;31(2-3):215-68
HSL5079
Christenson V.
Drug companies offer major discounts to uninsured.
J Law Med Ethics 2005 Summer;33(2):399-403
HSL5084
Kahn JP.
Lessons in conflict of interest: the construction of the martyrdom of David Healy and the dilemma of bioethics.
Am J Bioeth 2005 Sum;5(3):W13
http://taylorandfrancis.metapress.com/(iiz3n4n1mkazbl45vc3o1i45)/app/home/contribution.asp?referrer=parent&backto=issue,31,34;journal,6,24;linkingpublicationresults,1:111605,1
HSL5326
Stiles GM.
Wyeth responds to criticism.
Md Med 2005 Aut;6(4):5,
HSL5356
van Mosseveld C.
Pharmaceutical expenditure compared across countries.
Can J Clin Pharmacol 2005 Fal;12(3):e269-75
http://www.cjcp.ca/pdf/CJCP_04-048_e269.pdf
HSL5427
Caulfield T.
Commentary: an independent voice?: conflicts of interest and research on ethical, legal and social issues.
Health Law Rev 2005;13(2-3):114-6
HSL5428
Caulfield T.
Legal and ethical issues associated with patient recruitment in clinical trials: the case of competitive enrolment.
Health Law Rev 2005;13(2-3):58-61
HSL1922
Offerhaus L.
[The pharmaceutical industry in scandal: Mercury or Aesculapius?]
Ned Tijdschr Geneeskd 2004 Dec 18;148(51):2554-6
HSL2095
Abraham J.
Pharmaceuticals, the state and the global harmonisation process.
Aust Health Rev 2004 Nov 8;28(2):150-60
http://www.aushealthreview.com.au/publications/articles/issues/ahr_28_2_081104/ahr_28_2_150-160.asp
HSL5395
Pecoul B.
New drugs for neglected diseases: from pipeline to patients.
PLoS Med 2004 Oct;1(1):e6
HSL5437
Gupta AS.
Intellectual capital as property.
Indian J Med Ethics 2004 Oct-Dec;1(4):115-6
HSL5870
Elliott C.
Pharma goes to the laundry: Public relations and the business of medical education.
Hastings Cent Rep 2004 Sep-Oct 01;34(5):18-23
HSL5313
Kamtekar R.
Why life-saving drugs should be public goals.
Indian J Med Ethics 2004 Jul-Sep;1(3):77-8
HSL2803
Lakoff , A.
The anxieties of globalization: antidepressant sales and economic crisis in Argentina
Soc Stud Sci 2004 Apr;34(2):247-69
HSL2804
Rasmussen N.
The moral economy of the drug company-medical scientist collaboration in interwar America.
Soc Stud Sci 2004 Apr;34(2):161-85
HSL1336
Zehnder S, Bruppacher R, Ruppanner H, Hersberger K.
Swiss community pharmacies' on the Web and pharmacists' experiences with E-commerce: longitudinal study and Internet-based questionnaire survey
J Med Internet Res 2004 Mar 3;6(1):e9
HSL2798
Lurk JT, DeJong DJ, Woods TM, Knell ME, Carroll CA.
Effects of changes in patient cost sharing and drug sample policies on prescription drug costs and utilization in a safety-net-provider setting.
Am J Health Syst Pharm 2004 Feb 1;61(3):267-72
http://www.ajhp.org/cgi/reprint/61/3/267
HSL2088
Bennett WM.
Ethical conflicts for physicians treating ESRD patients.
Semin Dial 2004 Jan-Feb;17(1):1-3
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1525-139X.2004.17102.x?cookieSet=1
HSL2787
Reinhardt UE.
Perspective: An information infrastructure for the pharmaceutical market.
Health Aff (Millwood) 2004 Jan-Feb;23(1):107-12
http://content.healthaffairs.org/cgi/content/full/23/1/107
HSL5208
Malavige GN.
Doctors, drug companies and medical ethics: a Sri Lankan perspective.
Indian J Med Ethics 2004 Jan-Mar;1(1):26
HSL5209
Guha A.
A comparison of codes of pharmaceutical marketing practices.
Indian J Med Ethics 2004 Jan-Mar;1(1):19-21
HSL5210
Dabade G.
Unhealthy drug donations.
Indian J Med Ethics 2004 Jan-Mar;1(1):18
HSL5211
Bal A.
Can the medical profession and the pharmaceutical industry work ethically for better health care?
Indian J Med Ethics 2004 Jan-Mar;1(1):17
HSL5213
Roy N.
Who rules the great Indian drug bazaar?
Indian J Med Ethics 2004 Jan-Mar;1(1):2-3
HSL1924
Collins K.
Profitable gifts: a history of the Merck Mectizan donation program and its implications for international health.
Perspect Biol Med 2004 Win;47(1):100-9
http://muse.jhu.edu/cgi-bin/access.cgi?uri=/journals/perspectives_in_biology_and_medicine/v047/47.1collins.html&session=85559565
HSL2090
Baker D.
A free market solution for prescription drug crises.
Int J Health Serv 2004;34(3):517-26
HSL2097
Drug costs: research and development costs: the great illusion.
Prescrire Int. 2004;13(69):32-6
HSL4241
Srivastava R, Chandra A, Kumar G.
Strategic imperatives for globalization of industries in developing countries: an Indian pharmaceutical industry example.
Health Mark Q 2004;22(1):57-69
HSL1465
Booth B, Zemmel R.
Quest for the best.
Nat Rev Drug Discov 2003 Oct;2(10):838-41
http://www.nature.com/cgi-taf/DynaPage.taf?file=/nrd/journal/v2/n10/abs/nrd1203_fs.html&dynoptions=doi1114941377
HSL2237
Morgan S, Mintzes B, Barer M.
The economics of direct-to-consumer advertising of prescription-only drugs: prescribed to improve consumer welfare?
J Health Serv Res Policy 2003 Oct;8(4):237-44
http://www.ingentaconnect.com/content/rsm/jhsrp/2003/00000008/00000004/art00009?token=0064162e19bdf34e6b63734f582a2f4876753375726f4f2858595c5f3b3b47675248283b247b742b597a3f246002d620437a
HSL1386
Vaithianathan R.
Supply-side cost sharing when patients and doctors collude.
J Health Econ 2003 Sep;22(5):763-80
HSL5886
Kuperman GJ, Gibson RF.
Computer physician order entry: benefits, costs, and issues.
Ann Intern Med 2003 Jul 1;139(1):31-9
http://www.annals.org/cgi/reprint/139/1/31.pdf
HSL1457
Chung RS, Taira DA, Noh C.
Alternate financial incentives in multi-tiered formulary systems to improve accountability for outcomes.
J Manag Care Pharm 2003 Jul-Aug;9(4):360-5
HSL5439
Kietinun S, Gupte MD, Sengupta A.
A clinical trial in a developing country: many questions, few answers.
Issues Med Ethics 2003 Jul-Sep;11(3):89-90
HSL2234
Olson BM, Armstrong EP, Grizzle AJ, Nichter MA.
Industry's perception of presenting pharmacoeconomic models to managed care organizations.
J Manag Care Pharm 2003 Mar-Apr;9(2):159-67
HSL1382
Vogel RJ, Ramachandran S, Zachry WM.
A 3-stage model for assessing the probable economic effects of direct-to-consumer advertising of pharmaceuticals.
Clin Ther 2003 Jan;25(1):309-29
HSL1446
Dubois RW.
Pharmaceutical promotion: don't throw the baby out with the bathwater.
Health Aff (Millwood) 2003 Jan-Jun;Suppl
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.96v1
HSL2108
Vogel RJ, Ramachandran S, Zachry WM.
A 3-stage model for assessing the probable economic effects of direct-to-consumer advertising of pharmaceuticals.
Clin Ther 2003 Jan;25(1):309-29
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VRS-4833JPP-S&_coverDate=01%2F31%2F2003&_alid=295787923&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=6242&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=dba690738e220c9c57bacf614e822901
HSL1377
Williams-Jones B, Corrigan OP.
Rhetoric and hype: where's the 'ethics' in pharmacogenomics?
Am J Pharmacogenomics 2003;3(6):375-83
HSL1430
Hill S, Freemantle N.
A role for two-stage pharmacoeconomic appraisal? Is there a role for interim approval of a drug for reimbursement based on modelling studies with subsequent full approval using phase III data
Pharmacoeconomics. 2003;21(11):761-7
HSL1452
de Lissovoy G.
Weighing the evidence: trends in managed care formulary decision making.
J Clin Psychiatry 2003;64
http://article.psychiatrist.com/home.asp
HSL2396
Kay J.
The Truth about Markets: Why Some Nations are Rich but Most Remain Poor
London: Penguin Books; 2003
http://www.penguin.co.uk/nf/Book/BookDisplay/0,,0_0140296727,00.html
HSL5407
McCabe AR.
A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
Suffolk Univ Law Rev 2003;36(3):787-819
HSL2619
Klassen TP.
Economic evaluations of immunoprophylaxis in infants at high risk for respiratory syncytial virus: shedding light or creating confusion?
Arch Pediatr Adolesc Med 2002 Dec;156(12):1180-1
http://archpedi.ama-assn.org/cgi/content/full/156/12/1180
HSL2863
Hollis A.
The importance of being first: evidence from Canadian generic pharmaceuticals.
Health Econ 2002 Dec;11(8):723-34
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12457372
HSL2866
Henry D, Lexchin J.
The pharmaceutical industry as a medicines provider.
Lancet 2002 Nov 16;360(9345):1590-5
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12443614
HSL5863
Coast J, Smith R, Karcher AM, Wilton P, Millar M.
Superbugs II: how should economic evaluation be conducted for interventions which aim to contain antimicrobial resistance?
Health Econ 2002 Oct 01;11(7):637-47
http://www3.interscience.wiley.com/cgi-bin/abstract/93521364/ABSTRACT
HSL2261
Stewart KA, Neumann PJ.
FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation.
Value Health 2002 Sep-Oct;5(5):389-96
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12201856
HSL2306
Neumann PJ, Zivin Bambauer K, Ramakrishnan V, Stewart KA, Bell CM.
Economic messages in prescription drug advertisements in medical journals.
Med Care 2002 Sep;40(9):840-5
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12218774
HSL5961
Just how tainted has medicine become?
Lancet 2002 Apr 6;359(9313):1167
http://linkinghub.elsevier.com/retrieve/pii/S0140673602081989
HSL2879
D'Mello B.
Transnational pharmaceutical corporations and neo-liberal business ethics in India.
J Bus Ethics 2002 Mar;36(1-2):165-85
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12625343
HSL2887
Cocconi G.
Independent clinical trials: a commentary.
Tumori 2002 Mar-Apr;88(2):85-8
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12088263
HSL2903
Berkowitz BA, Sachs G.
Life Cycle of A Block Buster Drug: Discovery and Development of Omeprazole (PrilosecTM)
Mol Interv 2002 Feb;2(1):6-11
http://molinterv.aspetjournals.org/cgi/content/full/2/1/6, http://molinterv.aspetjournals.org/cgi/reprint/2/1/6,
HSL2157
Wolfe SM.
The destruction of medicine by market forces: teaching acquiescence or resistance and change?
Acad Med 2002 Jan;77(1):5-7
http://www.academicmedicine.org/cgi/content/full/77/1/5
HSL2895
Calfee JE.
The role of marketing in pharmaceutical research and development.
Pharmacoeconomics 2002;20
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12457428
HSL2901
Bode UH, Geisler EP.
[Medical ethics as output of economically motivated industrial objectives].
Wien Med Wochenschr. 2002;152(13-14):309-12
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12168510
HSL5069
Kamm MA.
Pharmacological treatment of irritable bowel syndrome--from concept to sales.
Eur J Surg Suppl 2002(587):10-5
HSL5320
Ghosh S.
Pills, patents, and power: state creation of gray markets as a limit on patent rights.
Fla J Int Law 2002 Spr;14(2):217-60
HSL5321
Nagan WP.
International intellectual property, access to health care, and human rights: South Africa v. United States.
Fla J Int Law 2002 Spr;14(2):155-91
HSL2775
Anonymous .
DTC advertising: Mixed messages
CMJ 2001 Dec;133(10):20
HSL5921
Steinman MA, Sands LP, Covinsky KE.
Self-restriction of medications due to cost in seniors without prescription coverage.
J Gen Intern Med 2001 Dec;16(12):793-9
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1525-1497.2001.10412.x
HSL5065
Elliott C.
Pharma buys a conscience.
Am Prospect 2001 Sep-Oct 24;12(17):16-20
HSL5440
Jesani A.
Calls for advertising and market reforms in health care.
Issues Med Ethics 2001 Jan-Mar;9(1):19
HSL5441
Mamdani B, Mamdani M.
Ethics of professional advertising.
Issues Med Ethics 2001 Jan-Mar;9(1):18
HSL5442
Malpani A.
Doctors should be allowed to advertise.
Issues Med Ethics 2001 Jan-Mar;9(1):16-7
HSL5443
Pandya SK.
Advertising remains unethical even in the digital age.
Issues Med Ethics 2001 Jan-Mar;9(1):15
HSL2405
Ainslie G.
Breakdown of Will
Cambridge: Cambridge University Press; 2001
http://www.cambridge.org/uk/catalogue/catalogue.asp?isbn=0521596947
HSL2736
Eichner , R MAROONICK, T J.
A review of direct-to-consumer (DTC) advertising and sales of prescription drugs: does DTC advertising increase sales and market share?
Journal of Pharmaceutical Marketing & Management 2001;13(4):19-42
HSL5989
Rai AK.
The information revolution reaches pharmaceuticals: balancing innovation incentives, cost, and access in the post-genomics era.
Univ Ill Law Rev 2001;2001(1):173-210
HSL336
Morgan S, Barer M, Evans R.
Health economists meet the fourth tempter: drug dependency and scientific discourse.
Health Econ 2000 Dec;9(8):659-67
http://www3.interscience.wiley.com/cgi-bin/abstract/76505087/ABSTRACT
HSL2996
Schwarting JS.
The pharmaceutical industry--to whom is it accountable?
N Engl J Med 2000 Nov 9;343(19):1416
HSL5315
Bhatt AD.
Clinical trial publications.
Issues Med Ethics 2000 Oct-Dec;8(4):119-21
HSL3001
Rubin P.
The New England Journal of Medicine - To whom is it accountable?
2000 Jun 27
HSL5089
D'Arcy PF, Hadden DR.
Are drug proprietary names necessary?
Adverse Drug React Toxicol Rev 2000 Jun;19(2):117-21
HSL5247
Ravindran GD.
The physician and the pharmaceutical industry: both must keep the patient's interests at heart.
Issues Med Ethics 1999 Jan-Mar;7(1):21-2
HSL5516
McGhan WF.
Employer and consumer perspectives.
Value Health 1998 Nov 01;1(4):237-42
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1524-4733.1998.140237.x
HSL557
Azimi NA, Welch HG.
The effectiveness of cost-effectiveness analysis in containing costs.
J Gen Intern Med 1998 Oct;13(10):664-9
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1525-1497.1998.00201.x
HSL4222
Tremayne WH.
Dollars & sense of the health care industry.
N J Med 1998 May 01;95(5):71-3
HSL5877
Guell RC.
Haggling for a patent: what a government would have to pay for prescription drug patents.
Health Econ 1997 Mar-Apr 01;6(2):179-85
http://www3.interscience.wiley.com/cgi-bin/abstract/14638/ABSTRACT
HSL5946
Edwards SS, Vinicky JK, Orlowski JP.
Conflicts of interest, conflicting interests, and interesting conflicts, part 2.
J Clin Ethics 1996 Spr 01;7(1):69-76
HSL5947
Orlowski JP, Vinicky JK, Edwards SS.
Conflicts of interest, conflicting interests, and interesting conflicts, Part 3.
J Clin Ethics 1996 Sum 01;7(2):184-6
HSL769
Neumann PJ, Zinner DE, Paltiel AD.
The FDA and regulation of cost-effectiveness claims.
Health Aff (Millwood) 1996 Fal;15(3):54-71
HSL850
Evans RG.
Manufacturing consensus, marketing truth: guidelines for economic evaluation.
Ann Intern Med 1995 Jul 1;123(1):59-60
HSL5878
Guell RC, Fischbaum M.
Toward allocative efficiency in the prescription drug industry.
Milbank Q 1995;73(2):213-30
HSL4034
Potter HP Jr.
Costs of drug advertising.
N Engl J Med 1988 Sep 22;319(12):798
HSL4007
Hurwitz MA, Caves RE.
Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals
Journal of Law and Economics 1988;31:299-320
HSL4024
Mossinghoff GJ.
Costs of drug advertising
New England Journal of Medicine 1988;319:798
HSL3775
Comanor WS.
The political economy of the pharmaceutical industry.
J Econ Lit 1986;24(3):1178-1217
HSL3779
Dingell JD.
Advertising prescription drugs to the public
New England Journal of Medicine 1986;314:524
HSL3806
Masson A, Rubin PH.
Warning: brief summaries may be hazardous to your health (and wealth) or the real issues in prescription drug advertising to consumers
Journal of Pharmaceutical Marketing & Management 1986;1(2):29-43
HSL3828
Turner J.
Antibiotic conference cancelled for second time
Lancet 1986;1:333
HSL3713
Eastman HC.
Report of the commission of inquiry on the pharmaceutical industry
1985
HSL3723
Mackowiak JI, Gagnon JP.
Effects of promotion on pharmaceutical demand.
Soc Sci Med 1985;20(11):1191-7
HSL3613
Gundry DRT.
The big spenders
British Medical Journal 1983;287:1884
HSL3524
Pharmaceutical prices in Canada: guiding principles for government policy
Pharmaceutical Manufacturers Association of Canada 1981 Feb
HSL3515
Leffler KB.
Persuasion or information? The economics of prescription drug advertising
Journal of Law and Economics 1981;24:45-74
HSL5914
Relman AS.
The new medical-industrial complex.
N Engl J Med 1980 Oct 23;303(17):963-70
HSL3371
Sevigny DC.
The ethical pharmaceutical industry and some of its economic aspects: an annotated bibliography
Addiction Research Foundation 1977
HSL3325
Cope JD.
The charges against O-T-C medicine advertising--are they deserved?
J Am Pharm Assoc 1976 Sep;16(9):500-4
HSL3330
Rheinstein PH, Mazis MB.
Regulation of O-T-C drug advertising: the FDA "prescription".
J Am Pharm Assoc 1976 Sep;16(9):505-6,
HSL3298
Cady J.
An estimate of the price effects of restrictions on drug price advertising
Economic Inquiry 1976;14:493-510
HSL3299
A critical look at the drug industry: how profits distort medicine
1976:31
HSL3315
Schwartzman D.
Promotional expenditures
The Johns Hopkins University Press 1976:182-211
HSL3331
Brooke P.
Promotional parameters: a preliminary examination of promotional expenditures
Journal of Drug Issues 1976;6(1):21-27
HSL3254
Woods D.
Prescription drugs and the patient's health.
Can Med Assoc J 1974 Dec 7;111(11):1269
HSL3269
Dryden A.
PMAC setting up board to pre-clear ads
Maclean Hunter 1974 Nov 18;79:3
HSL3252
Turner J.
Weaknesses in the system of promoting and marketing drugs
Journal of Drug Issues 1974;4:260-263
HSL3218
Torrance GM.
The influence of the drug industry in Canada’s health system
1972 Jan:48
HSL2713
Montgomery DB, Silk .
Estimating dynamic effects of market communications expenditures.
Management Sci 1972;18:B485-B501
Nil
HSL3185
MacDermot HE.
Readers write about the journal
CMAJ 1971;103:182
HSL3208
Steele H.
Prices & proftis in the drug industry; an economist’s view.
New Physician 1971;20:146-159